Enrica Balza

Title: Enrica Balza: Pioneering Innovations in Monoclonal Antibodies

Introduction

Enrica Balza, an accomplished inventor based in Genoa, Italy, has made significant contributions to the field of biomedical research with her innovative patents. With two patents to her name, she has focused on advancements in monoclonal antibodies, which are crucial for diagnostic and therapeutic applications in oncology.

Latest Patents

Enrica's latest patents showcase her expertise in identifying cancer markers and improving targeted therapies. Her first patent details a "Monoclonal antibody and its use for the identification of the oncofetal isoform of fibronectin (B-FN) for diagnosis or therapy." This invention describes the epitope localized on FNIII-repeat, which are normally cryptic but become unmasked through the insertion of FNIII-B into the fibronectin molecule. It also highlights the antibodies or their fragments capable of recognizing this specific epitope.

The second patent, "Selective targeting of tumor vasculature using antibody molecules," delves into targeting tumoral vasculature in vivo using a human recombinant scFv, L19, which is directed at the angiogenesis marker ED-B domain of fibronectin. The invention discusses preferred embodiments that utilize a complete human IgG1 with variable regions of L19, along with a mini-immunoglobulin formed by fusing scFv L19 to the constant CH4 domain of a secretory IgE isoform. This provides various in vivo behaviors of antibody formats that can be exploited for diverse diagnostic and therapeutic needs in clinical settings.

Career Highlights

Throughout her career, Enrica Balza has demonstrated commendable prowess in her field. She has collaborated with prominent organizations such as Philogen S.p.a. and Bayer Schering Pharma AG, where she contributed to pivotal research and development projects aimed at advancing medical therapies through innovative antibody applications.

Collaborations

Enrica has worked alongside esteemed professionals in the industry, including Laura Borsi and Patrizia Castellani, who have been instrumental in the development and implementation of her inventive ideas. These collaborations have fostered a synergistic environment that enhances the research and innovation process.

Conclusion

Enrica Balza is a remarkable inventor whose work in monoclonal antibodies is paving the way for breakthroughs in cancer diagnosis and therapy. Her dedication to research and innovation, combined with her collaborative efforts, continues to impact the medical field significantly. As she moves forward, her inventions hold the promise of improving therapeutic outcomes and advancing our understanding of oncological diseases.